Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure
Department of Pediatrics; Program in Molecular Medicine
Adult; Anti-HIV Agents; Female; HIV Infections; *HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Nevirapine; Pregnancy; Pregnancy Complications, Infectious
Immunology and Infectious Disease | Pediatrics
The safety, toxicity and pharmacokinetics of nevirapine were studied in HIV-infected pregnant women beginning chronic therapy late in the third trimester and in their infants. Initial dose pharmacokinetic profiles in the pregnant women were similar to those seen in nonpregnant adults. Serum nevirapine concentrations fell below the 100-ng/ml target concentration by Day 7 of life in four infants, suggesting that nevirapine elimination is accelerated in these infants compared with newborns whose mothers receive only a single intrapartum nevirapine dose.
Pediatr Infect Dis J. 2001 Aug;20(8):803-5. Link to article on publisher's website
The Pediatric infectious disease journal
Mirochnick M, Siminski S, Fenton T, Lugo M, Sullivan JL. (2001). Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure. Immunology/Infectious Disease. Retrieved from https://escholarship.umassmed.edu/peds_immunology/17